Últimas noticias sobre AbCellera Biologics (NASDAQ:ABCL) Bolsa

AbCellera Biologics

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

AbCellera Biologics Inc

Forrester Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORR#NASDAQ">FORR</a>) reported quarterly earnings of $0.29 per share which missed the analyst consensus estimate of $0.34 by 14.71 percent. This is a 34.09 percent decrease over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $102.527 million which beat the analyst consensus estimate of $101.944 million by 0.57 percent. This is a 9.61 percent decrease over sales of $113.431 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

FORR

Forrester Res Q3 2024 Adj. EPS $0.29 Misses $0.34 Estimate, Sales $102.527M Beat $101.944M Estimate

Guidance

B&G Foods Sees FY24 Net Sales $1.920B-$1.950B Vs $1.951B Est.; Adj. Diluted EPS $0.67-$0.77

Cytek Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.02) by 150 percent. The company reported quarterly sales of $51.500 million which beat the analyst consensus estimate of $50.696 million by 1.59 percent. This is a 7.29 percent increase over sales of $48.000 million the same period last year.

CTKB

Cytek Biosciences Q3 2024 GAAP EPS $0.01 Beats $(0.02) Estimate, Sales $51.500M Beat $50.696M Estimate

Full year fiscal 2025 guidance:2
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">Current</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GAAP</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">$2,369</td>
<td colspan="1" rowspan="1">$2,391</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating margin3</td>
<td colspan="1" rowspan="1">23.0&nbsp;%</td>
<td colspan="1" rowspan="1">23.2&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">EPS</td>
<td colspan="1" rowspan="1">$5.78</td>
<td colspan="1" rowspan="1">$5.87</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP4</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted revenue</td>
<td colspan="1" rowspan="1">$2,353</td>
<td colspan="1" rowspan="1">$2,375</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted operating margin</td>
<td colspan="1" rowspan="1">22.7&nbsp;%</td>
<td colspan="1" rowspan="1">22.8&nbsp;%</td>
</tr>
</tbody>
</table>
</figure>
<a href="https://mma.prnewswire.com/media/2549531/JKHY_Key_Call_Outs___Q1_FY25.html"><img src="https://mma.prnewswire.com/media/2549531/JKHY_Key_Call_Outs___Q1_FY25.jpg" alt="Key Call-Outs" /></a>

JKHY

Jack Henry & Associates Sees FY25 EPS $5.78-$5.87 Vs $5.83 Est.; Revenue $2.353B-$2.375B Vs $2.37B Est.

Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) narrows FY2024 sales outlook from $495.00 million-525.00 million to $500.00 million-510.00 million.

SWIM

Latham Group Narrows FY2024 Sales Guidance from $495.00M-525.00M to $500.00M-510.00M  VS Est. 512.39M

Meme cryptocurrency Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) has experienced a surge in trading volume and price activity leading up to the <a href="https://www.benzinga.com/topic/2024-election">2024 presidential election.</a>
A Benzinga poll asks readers to choose whether a victory by Donald Trump or Kamala Harris in the election could have a more positive impact on Dogecoin in 2025.
What Happened: Dogecoin is up 12% to $0.1761 on Tuesday, with the meme cryptocurrency seeing increased activity likely related to the 2024 election <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41734897/elon-musks-doge-department-mention-gives-dogecoin-boost-to-top-of-daily-gainers-memecoin-s">and positive mentions </a>of the Department of Government Efficiency, or D.O.G.E. for short, by Elon Musk.
Musk is expected to join the Trump administration if the former president wins the 2024 election. In this role, Musk would seek to cut government inefficiencies and unnecessary departments, a role labeled under the D.O.G.E.
The Tesla CEO and billionaire mentioned D.O.G.E. during his<a href="https://www.benzinga.com/general/education/24/11/41752565/if-you-invested-1-000-in-tesla-stock-the-first-time-elon-musk-was-on-the-joe-rogan-podcast-here"> most recent appearance</a> Monday on "The Joe Rogan Experience" podcast, which is likely contributing to Dogecoin's strong movement on Tuesday.
"For Dogecoin's future in 2025, who would be the better president: Kamala Harris or Donald Trump?" Benzinga recently asked.
The results were:
<ul>
<li>Donald Trump: 72%</li>
<li>Kamala Harris: 28%</li>
</ul>
The Benzinga poll found that respondents believe Trump would be more favorable for the future of Dogecoin, which may not come as a surprise given the former president&#8217;s reputation as a more pro-crypto leader.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent110524">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
What's Next: Trump, who previously <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38749745/if-you-invested-1-000-in-bitcoin-when-donald-trump-said-the-cryptos-value-was-based-on-thi">spoke out against Bitcoin, </a>reversed course and has appealed to cryptocurrency investors ahead of the 2024 election.
If Trump wins the 2024 election, cryptocurrency investors expect the price of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and other cryptocurrencies to rise with a more crypto-friendly government in place and the likelihood that SEC Chair Gary Gensler will be replaced.
While Harris has not been as vocal on cryptocurrency as Trump, there is belief that she <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41322645/mark-cuban-defends-kamala-harris-crypto-knowledge-appears-to-take-dig-at-trump-for-selling">could look to advance</a> the sector forward if she wins the election.
Either way, Dogecoin could see high volatility during the week as the 2024 election outcome is expected to take some time to make official.
With a price of $0.1761 on Tuesday, Dogecoin is nearing its one-month high of $0.1792.
Over the last 52 weeks, Dogecoin has traded between $0.07028 and $0.2266. Dogecoin hit all-time highs of $0.7376 back in May 2021.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41410605/if-you-invested-100-in-dogecoin-when-elon-musk-first-tweeted-about-the-meme-crypto-heres-h">If You Invested $100 In Dogecoin When Elon Musk First Tweeted About The Meme Crypto, Here&#8217;s How Much You&#8217;d Have Today</a></li>
</ul>
The study was conducted by Benzinga from Nov. 4 through Nov. 5, 2024, and included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 134 adults.
Image created with Shutterstock and Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Exclusives

$BTC

$DOGE

Dogecoin Jumps On Election Day: Poll Asks If Trump Or Harris Victory Will Spark 2025 Rally

WIIM

Devon Energy shares are trading higher following a Q3 earnings beat.

Ashford Hospitality Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHT#NYSE">AHT</a>) reported quarterly AFFO of $(1.71) per share which missed the analyst consensus estimate of $(0.97) by 76.29 percent. This is a 311.11 percent decrease over earnings of $0.81 per share from the same period last year. The company reported quarterly sales of $276.60 million which beat the analyst consensus estimate of $268.97 million by 2.84 percent. This is a 19.36 percent decrease over sales of $343.01 million the same period last year.

Ashford Hospitality Trust Q3 2024 AFFO $(1.71) Misses $(0.97) Estimate, Sales $276.60M Beat $268.97M Estimate

Jack Henry &amp; Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JKHY#NASDAQ">JKHY</a>) reported quarterly earnings of $1.63 per share which beat the analyst consensus estimate of $1.61 by 1.24 percent. This is a 17.27 percent increase over earnings of $1.39 per share from the same period last year. The company reported quarterly sales of $600.98 million which beat the analyst consensus estimate of $600.11 million by 0.15 percent. This is a 5.18 percent increase over sales of $571.37 million the same period last year.

Jack Henry & Associates Q1 EPS $1.63 Beats $1.61 Estimate, Sales $600.98M Beat $600.11M Estimate

B&amp;G Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.20 by 35 percent. The company reported quarterly sales of $461.10 million which missed the analyst consensus estimate of $473.12 million by 2.54 percent. This is a 8.28 percent decrease over sales of $502.73 million the same period last year.

B&G Foods Q3 2024 Adj EPS $0.13 Misses $0.20 Estimate, Sales $461.10M Miss $473.12M Estimate

NHI is updating its 2024 annual guidance range which includes the following:
NAREIT FFO per diluted common share to a range of $4.39 - $4.41 from $4.50 - $4.54;
Normalized FFO per diluted common share to a range of $4.43 - $4.44 from $4.52 - $4.56; and
Normalized FAD to a range of $201.8 million - $202.5 million from $200.1 million - $201.8 million;
NAREIT FFO and Normalized FFO revised guidance is primarily due to lower cash lease revenue and interest income assumptions, and a $3.6 million non-cash increase to the credit loss reserve attributable to Senior Living Management. This was partially offset by acquisitions closed since August 2024 funded primarily with forward equity proceeds;
Normalized FAD revised guidance is primarily due to acquisitions closed since August 2024 offset by lower cash lease revenue and interest income assumptions attributable to Senior Living Management.

National Health Investors Updates FY24 NAREIT FFO Per Diluted Share From $4.50-$4.54 To $4.39-$4.41; Normalized FFO Per Diluted Share From $4.52-$4.56 To $4.43-$4.44

Aviat Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVNW#NASDAQ">AVNW</a>) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.03) by 2800 percent. This is a 245 percent decrease over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $88.43 million which missed the analyst consensus estimate of $94.21 million by 6.14 percent. This is a 1.75 percent increase over sales of $86.91 million the same period last year.

AVNW

Aviat Networks Q1 Adj $(0.87) Misses $(0.03) Estimate, Sales $88.43M Miss $94.21M Estimate

Vtex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTEX#NYSE">VTEX</a>) lowers FY2024 sales outlook from $231.00 million-235.00 million to $230.00 million-232.00 million.

VTEX

Vtex Lowers FY2024 Sales Guidance from $231.00M-235.00M to $230.00M-232.00M.

MASI

Masimo Sees Q4 Revenue $581M-$611M; Q4 Adj. EPS $1.35-$1.50

Vtex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTEX#NYSE">VTEX</a>) sees Q4 sales of $64.800 million-66.800 million vs $67.57 million estimate.

Vtex Sees Q4 Sales $64.800M-66.800M vs $67.57M Est.

Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) reported quarterly losses of $(0.98) per share which beat the analyst consensus estimate of $(1.02) by 3.92 percent. The company reported quarterly sales of $12.500 million which beat the analyst consensus estimate of $11.199 million by 11.62 percent.

SNDX

Syndax Pharmaceuticals Q3 2024 GAAP EPS $(0.98) Beats $(1.02) Estimate, Sales $12.500M Beat $11.199M Estimate

Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. The company reported quarterly sales of $45.086 million which beat the analyst consensus estimate of $43.484 million by 3.68 percent. This is a 10.62 percent increase over sales of $40.758 million the same period last year.

TMCI

Treace Medical Concepts Q3 2024 GAAP EPS $(0.25) Beats $(0.27) Estimate, Sales $45.086M Beat $43.484M Estimate

Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) reported quarterly earnings of $1.30 per share which beat the analyst consensus estimate of $1.14 by 14.04 percent.

Devon Energy Q3 2024 GAAP EPS $1.30 Beats $1.14 Estimate

Coupang (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.01 by 500 percent. The company reported quarterly sales of $7.90 billion which beat the analyst consensus estimate of $7.76 billion by 1.79 percent. This is a 27.75 percent increase over sales of $6.18 billion the same period last year.

CPNG

Coupang Q3 2024 Adj EPS $0.06 Beats $0.01 Estimate, Sales $7.90B Beat $7.76B Estimate

Ever wondered <a href="https://www.benzinga.com/personal-finance/24/10/41193824/are-you-rich-enough-to-be-in-the-top-1-heres-both-the-income-and-net-worth-you-need-to-rank-amon">how your finances measure up?</a> You're not alone. We often think about where we stand compared to others financially – though few of us like to admit it. Getting a sense of your financial health can be motivating, especially when it's not about competition but about setting realistic goals for yourself.&nbsp;
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/62-years-old-with-1-mil-saved">I&#8217;m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?</a></li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved? <a href="https://www.benzinga.com/money/red-ventures" target="_blank" rel="noreferrer noopener">The percentage may shock you</a>.</li>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
</ul>
What is Net Worth, Really?
Before diving into numbers, clarifying what "net worth" means is important. Simply put, it's what you own (assets) minus what you owe (liabilities). Assets include things like your home, car, investments and savings. Liabilities are things like mortgages, credit card debt and student loans. Think of net worth as a quick snapshot of your financial health. It's a bigger picture than income alone, revealing how much you've kept.
See Also: Can you guess how many retire with a $5,000,000 nest egg? &#8211;<a href="https://www.benzinga.com/money/retire-5mil-nest-egg"> How does it compare to the average?</a>
Net Worth by Income Level
According to the Federal Reserve's latest data, here's how net worth varies across different income brackets:
<ul>
<li>Under $34,600: Median net worth of $14,000, average of $129,700</li>
<li>$34,600-$59,499: Median of $71,000, average of $218,700</li>
<li>$59,500-$91,899: Median of $159,300, average of $385,400</li>
<li>$91,900-$153,099: Median of $307,200, average of $636,800</li>
<li>$153,100-$245,399: Median of $747,000, average of $1,264,700</li>
<li>$245,400 and higher: Median of $2,556,200, average of $6,629,600</li>
</ul>
Upper-income households in the U.S. generally have a net worth significantly higher than lower-income households. According to Pew Research Center, the median net worth of upper-income households is roughly 7.3 times greater than that of middle-income households, and 75 times that of lower-income households.
Trending: Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a>
What You Can Learn from the Data
There are a few standout takeaways:
Median vs. Average: The U.S. household median net worth is $192,700, while the average is around $1.06 million. The gap highlights how high-net-worth individuals skew the overall average.
Age Matters: Net worth tends to peak for those aged 65-74, averaging around $1.78 million. Years of saving and investing build up.
Education's Impact: A college degree matters here – graduates have over 11 times the net worth of people without a high school diploma.
Location, Location, Location: Urban dwellers typically have higher net worthy than those in rural areas, largely due to property values.
Wealth Gap: Unfortunately, the racial wealth gap remains stark, with white households holding considerably higher net worthy on average than Black and Latino households.
Trending: According to Vanguard&#8217;s Advisor&#8217;s Alpha Study, working with a financial advisor can result in approximately 3% higher net returns annually, <a href="https://www.benzinga.com/money/3-percent-advantage-financial-advisor" target="_blank" rel="noreferrer noopener">here are the benefits of partnering with a financial advisor and how to find the right one near you in minutes.</a>
Steps to Boost Your Net Worth
Regardless of where you currently fall, there are practical ways to improve your financial standing:
<ul>
<li>Pay Off High-Interest Debt: Start with credit card balances and other high-interest debts, which can drain your finances fast.</li>
</ul>
<ul>
<li>Save and Invest: Aim to set aside at least 20% of your income and automate it if you can. Investing early helps, too.</li>
</ul>
<ul>
<li>Leverage Retirement Accounts: Contribute to 401(k)s or IRAs, especially if your employer matches contributions.</li>
</ul>
<ul>
<li>Diversify: Spread your investments across stocks, bonds and real estate to manage risk and grow wealth.</li>
</ul>
<ul>
<li>Find Extra Income Streams: Side hustles, freelance work or passive income can boost your finances.</li>
</ul>
See Also: <a href="https://www.benzinga.com/money/100k-cd">$100K Sitting In A CD Account, Should I Move Money Into The Stock Market?</a>
<ul>
<li>Keep Learning: Educate yourself about personal finance and stay updated on tax strategies and investment options.</li>
</ul>
<ul>
<li>Live Below Your Means: Resist lifestyle inflation even as your income grows. Focus on assets, not material things.</li>
</ul>
<ul>
<li>Invest in Yourself: Whether it's more education or a new skill, growing your potential can lead to better income.</li>
</ul>
<ul>
<li>Check In on Your Goals: Adjust your financial plan as your life and income evolve.</li>
</ul>
<ul>
<li>Seek Professional Guidance: A <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">financial advisor can help you</a> strategize if it feels overwhelming.</li>
</ul>
Comparing your finances to others can motivate you, but remember that everyone's journey is different. Focus on realistic, personal goals that fit your life. Building wealth takes time – it's a marathon, not a sprint. With steady, smart choices, you'll see growth in your net worth over time. Regardless of where you stand now, there's always room to move toward a more secure financial future.
This story was updated to reflect updated research numbers for upper household income net worth vs. lower-income households.
Read Next:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? &#8211; <a href="https://www.benzinga.com/money/retire-5mil-nest-egg" target="_blank" rel="noreferrer noopener">How does it compare to the average?</a></li>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
</ul>

Personal Finance

Are You Richer Or Poorer Than Your Peers? Here's A Look At The Average Net Worth For Your Income

Tracking Baker Brothers Portfolio - Q2 2024 Update

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.

AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week

AbCellera: A Platform To Pipeline Transition

Here are the major earnings after the close today

AbCellera Biologics ( ($ABCL) ) has shared an update. AbCellera reported its Q3 2024 financial results, highlighting a strategic expansion with Eli...

AbCellera Biologics Expands Partnership and Advances Pipeline

AbCellera Biologics Inc. 2024 Q3 - Results - Earnings Call Presentation

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

TD Cowen analyst Brendan Smith maintained a Buy rating on AbCellera Biologics (ABCL – Research Report) yesterday. The company's shares closed yeste...

TD Cowen Remains a Buy on AbCellera Biologics (ABCL)

Abcellera Biologics, Inc. ( ($ABCL) ) has released its Q3 earnings. Here is a breakdown of the information Abcellera Biologics, Inc. presented to i...

AbCellera Biologics Reports Q3 2024 Financial Results

Benchmark Co. analyst Robert Wasserman maintained a Hold rating on AbCellera Biologics (ABCL – Research Report) today. The company's shares closed ...

AbCellera Biologics (ABCL) Receives a Hold from Benchmark Co.

ABBV

ABCL

ABSI

ACAD

AKRO

ALAB

ANDE

AOSL

APLE

AQST

ARGNF

ARGX

ATUS

AZPN

BCOV

BCRX

BCYC

BEIGF

BGNE

BWXT

CDNA

CENX

CLLS

CRGY

CRUS

CSTL

EGHT

EWTX

EXAI

HDSN

HIMS

HOLX

ICHR

ILMN

IMCR

INCY

INSM

INSP

ITUB

KYMR

LSCC

MDGL

METC

NTST

NVTS

OTTR

PARR

RARE

REPL

RLAY

ROIV

RVMD

RVMDW

RXRX

RYTM

SDGR

Press Releases

AbCellera Reports Q1 2024 Business Results

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

AbCellera Reports Q2 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in September

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

AbCellera to Present at Upcoming Investor Conferences in November 2024

AbCellera Reports Q3 2024 Business Results

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Azenta

BioLife Solns

Bruker

ChromaDex

Charles River Laboratories International, Inc. Common Stock

Charles River

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

AbCellera Biologics

Noticias

Últimas noticias sobre AbCellera Biologics (NASDAQ:ABCL) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL